Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olmesartan medoxomil, quantity: 20 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: hypromellose; purified water; hyprolose; lactose monohydrate; magnesium stearate; microcrystalline cellulose; titanium dioxide; iron oxide yellow; macrogol 4000 - indicated for the treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hypromellose; purified water; microcrystalline cellulose; hyprolose; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 4000 - indicated for the treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; hyprolose; purified water; microcrystalline cellulose; hypromellose; titanium dioxide; iron oxide yellow; macrogol 4000 - indicated for the treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Canada - English - Health Canada

american regent, inc - iron (iron dextran complex) - solution - 50mg - iron (iron dextran complex) 50mg - iron preparations

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 6.75 mg - drug delivery system, transdermal - excipient ingredients: povidone; dl-alpha-tocopherol; sodium metabisulfite; ascorbyl palmitate; methylated trimethylated silica; heptane - parkinson's disease, neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome, neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 2.25 mg - drug delivery system, transdermal - excipient ingredients: dl-alpha-tocopherol; povidone; ascorbyl palmitate; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease, neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome, neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 18 mg - drug delivery system, transdermal - excipient ingredients: povidone; ascorbyl palmitate; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 13.5 mg - drug delivery system, transdermal - excipient ingredients: ascorbyl palmitate; povidone; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 9 mg - drug delivery system, transdermal - excipient ingredients: ascorbyl palmitate; povidone; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 4.5 mg - drug delivery system, transdermal - excipient ingredients: dl-alpha-tocopherol; ascorbyl palmitate; povidone; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.